Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenacaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.97 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.97 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.61 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenacaine SCHEMBL30185782 | 0.98 | SCN1A (0.94) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| Phenacaine SCHEMBL24365 | 0.98 | SCN1A (1.00) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| Phenacaine SCHEMBL16070026 | 0.98 | SCN1A (1.00) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| Phenacaine SCHEMBL1652314 | 0.95 | SCN1A (0.94) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| SCHEMBL11234205 | 0.81 | ADRA2A (0.83) | SCN1ASCN2ASCN3AADRA2AALDH1A1 | |
| SCHEMBL9804078 | 0.80 | SCN1A (0.68) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| SCHEMBL9804085 | 0.80 | SCN1A (0.68) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| SCHEMBL8047968 | 0.77 | ADRA2A (0.69) | SCN1ASCN2ASCN3AADRA2AMEN1 | |
| SCHEMBL19272266 | 0.76 | KMT2A (0.81) | SCN1ASCN2ASCN3AMEN1LMNA | |
| SCHEMBL17471481 | 0.76 | SCN1A (0.63) | SCN1ASCN2ASCN3AADRA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105142611-B | Topical composition and the method for treating topical condition | 佩丽泰克医药有限公司 | 2019-06-04 | — | — | CN | claimed |
| CN-109562281-A | Prodrugs of phenolic TRPV1 agonists for use in combination with local anesthetics and vasoconstrictors for improving local anesthesia | 同心镇痛药物公司 | 2019-04-02 | — | — | CN | claimed |
| CN-108883065-A | Extended duration local anesthetic formulations | 万蒂斯制药公司 | 2018-11-23 | — | — | CN | claimed |
| CN-105031742-B | It is a kind of that there is antimicrobial and anticoagulation property catheter lock solution | 贝克顿·迪金森公司 | 2018-06-01 | — | — | CN | claimed |
| US-8691283-B2 | Standardized bee venom preparation | KIM CHRISTOPHER M (KR) | 2014-04-08 | — | — | US | claimed |
| US-20130216517-A1 | STANDARDIZED BEE VENOM PREPARATION | KIM CHRISTOPHER M (KR) | 2013-08-22 | — | — | US | claimed |
| US-8440234-B2 | Standardized bee venom preparation suitable for administration by injection comprising; Bee venom treatment without the sting | KIM CHRISTOPHER M (KR) | 2013-05-14 | — | — | US | claimed |
| WO-2008113992-A2 | GEL COMPOSITIONS COMPRISING UREA DERIVATIVES | PLIVA HRVATSKA D.O.O. (HR) | 2008-09-25 | — | — | WO | claimed |
| WO-2008102127-A2 | GEL FORMING COMPOUNDS | PLIVA HRVATSKA D.O.O. (HR) | 2008-08-28 | — | — | WO | claimed |
| EP-1027015-A4 | CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE | GALIN MILES A (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1027015-A1 | CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE | Galin, Miles A. (US) | 2000-08-16 | — | — | EP | claimed |
| CN-1251979-A | Controlled release of drugs in the anterior chamber of the eye | MILES A GALIN (US) | 2000-05-03 | — | — | CN | claimed |
| US-5972326-A | Controlled release of pharmaceuticals in the anterior chamber of the eye | IOLTECH (FR) | 1999-10-26 | — | — | US | claimed |
| US-5898035-A | Formulations of haloalkylamines and local anesthetic and methods for the treatment of reflex sympathetic dystrophy (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1999-04-27 | — | — | US | claimed |
| WO-1998041171-A1 | CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE | GALIN MILES A (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0850054-A1 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997007793-A1 | FORMULATIONS OF HALOALKYLAMINES AND LOCAL ANAESTHETICS AND METHODS FOR THE TREATMENT OF REFLEX SYMPATHETIC DYSTROPHY (RSD) | NEW YORK MEDICAL COLLEGE (US) | 1997-03-06 | — | — | WO | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |